RECCE PHARMACEUTICALS LTD

Recce Pharmaceuticals' R327G Shows Promise in Phase II ABSSSI Trial

- Recce Pharmaceuticals' Phase II trial of R327G for ABSSSI reaches a milestone with 20 of 30 patients dosed, indicating strong progress. - Interim data reveals that all patients treated with R327G achieved either a complete cure or notable improvement, demonstrating promising efficacy. - The trial remains on track for completion by the end of 2024, potentially leading to a new synthetic anti-infective topical therapy. - No serious adverse events were reported, reinforcing R327G's favorable safety profile in treating acute bacterial skin infections.